Quest Diagnostics Reports Strong Performance in Second Qu... (presented because management believes th...)

Quest Diagnostics Reports Strong Performance in Second Quarter 2009

Date:7/21/2009

presented because management believes that it is a useful adjunct to estimated cash from operations under accounting principles generally accepted in the United States since it is a meaningful measure of the company's ongoing operating performance. Estimated cash from operations before the payment of the previously announced NID settlement is not a measure of financial performance under accounting principles generally accepted in the United States and should not be considered as an alternative to estimated cash from operations. See footnote 7 to the attached tables.

This earnings release, including the attached financial tables, is available online in the Press Room section at www.QuestDiagnostics.com.

TABLES FOLLOW

Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations
For the Three and Six Months Ended June 30, 2009 and 2008
(in millions, except per share and percentage data)
(unaudited)

Three Months Ended Six Months Ended
June 30, June 30,
2009 2008 2009 2008

Net revenues $1,901.8 $1,837.9 $3,709.8 $3,622.5

Operating costs and
expenses:
Cost of services 1,100.2 1,083.5 2,153.7 2,142.1
Selling, general and
administrative 448.8 438.0 873.1 873.1
Amortization of intangible
assets 9.4 9.9 18.4 19.2
Other operating income, net (15.9) (1.6) (15.8) (0.3)
Total operating costs and
expenses
'/>"/>
SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved
0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
2. The 7 Key Questions About the Schwarzenegger/Nunez Health Care Compromise
3. LifeQuest Announces End of Immunity Health Challenge Contest
4. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
5. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
6. Study Questions Dead-End Cancer Clinical Trials
7. 6 Years Later, 9/11 Health Questions Linger
8. U.S. Physicians Question Presidential Candidates
9. RFID Implant Cancer Questions Concern Patients
10. Study Questions Genetic Screening for Treatable Diseases
11. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam

Post Your Comments:

(Date:12/17/2009)... Is Taking Their Leading Master of Science in Human Resource ... ... Fla. (PRWEB) December 17, 2009 -- Open enrollment has begun ... which is ideal for working professionals whose busy schedules can’t ... in Human Resource Development debuting online in March 2010, location ...

(Date:12/17/2009)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today ... transaction to sell an aggregate of 4,784,689 primary shares ... a price of $2.09 per share, raising aggregate gross ... the financing to close on or about December 22, ... A shelf registration statement relating to the shares of ...

(Date:12/17/2009)... Mechanism to Pursue Approval in Multiple Jurisdictions ... - Labopharm Inc. (TSX: DDS; NASDAQ: ... the regulatory approval process for its twice-daily ... Procedure (DCP). The DCP provides an efficient ... pursue regulatory approval for a medicinal product ...

(Date:12/17/2009)... Calif., Dec. 17 Abaxis, Inc. (Nasdaq: ... point-of-care blood analysis instruments and rapid tests for ... that it has entered the production animal diagnostics ... Influenza Antigen Test. This is a USDA-licensed test ... chickens, turkeys and ducks. The disposable, non-instrumented device, ...

(Date:12/17/2009)... Valerie VanBooven RN BSN author and elder care expert announces the ... Success, Courage and Strength.” Valerie is a contributing author and ... books to be written all year. Now released in paperback, ... office locally. , ... St. Louis, MO (PRWEB) December ...

Breaking Medicine News(10 mins):Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2 Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3 Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 2 Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 3 Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 2 Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 3 Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 2 Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 3 Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 4 Health News:Valerie VanBooven RN BSN Announces the Release of her 3rd Book Celebrating Caregivers and Families 2 Health News:Valerie VanBooven RN BSN Announces the Release of her 3rd Book Celebrating Caregivers and Families 3

[0] A World-Class HR Master's Degree Is Now Within Reach – 100% Online [0] Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million [0] Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe [0] ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit [0] Valerie VanBooven RN BSN Announces the Release of her 3rd Book Celebrating Caregivers and Families

... children who lived close to main roads had a significant ... by 'The Lancet' medical journal.// ,The U.S. researchers ... 10-18, growing up near the roadways (within 500 metres of ... exhaust fumes. Traffic pollution prevents the lungs from developing properly, ...

... of compulsory licenses for inexpensive versions of heart disease ... well with pharmaceutical bigwigs. Health Minister, Mongkol Songkhla, confirmed ... ,According to the Health Minister, the drugs ... did not elaborate on whether the drugs would be ...

... A University of Rochester research review emphasizes that SAD ... should be treated as such. Their review article ... ,Lead author Stephen Lurie, M.D., Ph.D., an assistant ... Medical Center, also noted that SAD is sometimes missed ...

... Scientists at UC Irvine have discovered that learning appears to ... hallmarks of Alzheimer's disease.// The finding suggests that the elderly, ... of this degenerative disease. The study appears in the Jan. ... ,This study with genetically modified mice is the first to ...

... is breast cancer or ovarian cancer, which is feared the most. ... actually die of lung// cancer, as revealed in a new report ... ,Even though men were prone to lung cancer in ... targets due to increase in women smokers. In 2000, lung cancer ...

... of the mineral selenium appear to reduce or slow ... selenium have been noted in HIV-positive patients, and evidence ... system function, the researchers report in the Jan. 22 ... ,"Those individuals who were treated with selenium displayed ...

Other Medicine News:Health News:Study Reviews Seasonal Affective Disorder 2 Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2 Health News:Selenium Supplements May Slow Progression of HIV: Report 2 Health News:Selenium Supplements May Slow Progression of HIV: Report 3

Children Living Near Roads are Prone to Lung Damages Thailand Goes Ahead With Licenses for Generic Drugs Study Reviews Seasonal Affective Disorder Learning Slows Physical Progression of Alzheimer's Disease: Study Additional Research Imperative on Lung Cancer in Women Selenium Supplements May Slow Progression of HIV: Report

(Date:12/17/2009)... Express Scripts, Inc. (Nasdaq: ESRX ), ... companies in North America, announced today results ... of seizure risk among epilepsy patients after ... study found no evidence that switching between ... substitution, was associated with increased emergency room ...

(Date:12/17/2009)... -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX ) ... Vice President, Sales and Commercial Affairs. In ... will be responsible for all commercial activities, including ... accordance with the collaboration agreement between the Company ... products that emerge from the Company,s pipeline. ...

(Date:12/16/2009)... Dec. 17 Cell Therapeutics, Inc. ... that on February 10, 2010 the U.S. ... Committee (ODAC) will review the New Drug ... of relapsed/refractory aggressive non-Hodgkin,s lymphoma (NHL). ODAC ... evaluates data concerning the efficacy and safety ...

[0] Express Scripts Study Finds No Association Between Anti-Epileptic Drug Switches and Increased Seizure Activity [0] Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs [0] Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010

... , - Novel Treatment Also Demonstrated ... in Depressive Symptoms, Positive data from ... the 8th,European Congress of Epileptology, Berlin, Germany, ... once daily,anti-epileptic agent, significantly reduced the frequency ...

... shows high prevalence of "bothersome" vaginal atrophy, symptoms among ... today at 19th Annual North American Menopause ... ... results of a,Phase 3 study for Ophena(TM) (ospemifene tablets) for the ...

Other Medicine Technology:New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 2 New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 3 New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 4 New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 5 New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy 6 QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy 2 QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy 3 QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy 4

New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy

... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...

... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...

... collagen hemostat. FirstStop is a non-friable, non-woven ... characteristics. It can easily be cut to ... FirstStop products are not dispersed when wet ... hemostasis is achieved. As the collagen forms ...

InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...

Medicine Products:

VasoSeal VHD KIT 3 VasoSeal VHD KIT 4 First Stop Hemacarotid Knitted

Quest Diagnostics Reports Strong Performance in Second Qu...(presented because management believes th...),Health